www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sinopharm unit inches toward vaccine breakthrough

By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
Share
Share - WeChat
A China National Biotech Group Co Ltd employee displays a COVID-19 inactive vaccine, which is under development and trials, at the company's research institute in Wuhan, capital of Hubei province, on April 10. [Photo/Xinhua]

State-owned CNBG teams up with partners to step up development of effective, lasting treatment for COVID-19

Chinese State-owned pharmaceutical giant Sinopharm Group has made substantial progress in developing vaccine candidates for the novel coronavirus that causes COVID-19.

China National Biotech Group Co Ltd, Sinopharm's vaccine and bioscience unit, announced on Monday that its second inactivated vaccine targeting the contagion won clinical trial approval from the National Medical Products Administration. The vaccine is codeveloped by a unit under CNBG-Beijing Institute of Biological Products Co Ltd-and the Chinese Center for Disease Control and Prevention.

On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.

Approved for clinical trials on April 12, the vaccine was the first inactivated vaccine worldwide to reach such a developed approval stage. The NMPA authorized its phase-1 and phase-2 human trials at the same time on that day through a fast-track channel based on solid results from preclinical trial studies.

"The world is racing to develop COVID-19 vaccines, yet it is not a competition between countries, but rather a race between humans and the virus," said Yang Xiaoming, president of CNBG.

Yang said it is quite encouraging to have developed inactivated vaccines against COVID-19.

Inactivated vaccines use nonliving viruses, bacteria or other pathogens that have lost disease-producing capacity to stimulate the immune system to develop an immune response.

Wang Junzhi, an academic at the Chinese Academy of Engineering, said China has laid a solid foundation to research inactivated vaccines in recent years, and inactivated vaccines have been widely used to fight hepatitis A, influenza, poliomyelitis, and hand, foot and mouth disease.

Yang added that China has distinctive advantages in developing vaccines against the disease thanks to the country's institutional features that can unite resources and efforts of different participants to concentrate on a specific program and target.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 在线观看免费黄视频 | 玖草资源在线 | 欧美一区亚洲二区 | 亚洲欧美另类专区 | 日本一视频一区视频二区 | 在线观看国产一区二区三区99 | 国产成版人视频网站免费下 | 免费 欧美 自拍 在线观看 | 美女很黄很黄免费 | 欧美成人私人视频88在线观看 | 国产在线精品一区二区三区不卡 | 久久网站在线观看 | 成年男女拍拍拍免费视频 | 久久久久久亚洲精品 | 久久免费精品国产视频 | 女人张开腿给男人捅 | 美女的被男人桶爽网站 | 国产在线观看网址你懂得 | 高清不卡毛片 | 日产一区两区三区四区 | 欧美激情免费观看一区 | 欧美不卡视频在线观看 | 牛人国产偷窥女洗浴在线观看 | 国产粗大猛烈18p | 成年女人永久免费观看片 | 亚色网站 | 亚洲欧美一区二区三区在线观看 | 波多野结衣一区二区三区88 | 99国产精品视频久久久久 | 可以看毛片的网址 | www.成年人 | 国产在线a | 亚洲一区在线视频 | 国产在线精品一区二区三区 | 久久精品中文字幕首页 | 精品日韩二区三区精品视频 | 亚洲精品人成网在线播放影院 | 国产精品九九 | 三级网址在线观看 | 欧美 日韩 国产 成人 在线观看 | 亚洲精品无码不卡在线播放he |